Medesis Pharma S.A. (76D.F)

1.1800 -0.0700 (-5.30%) As of 09:17AM CEST. Market open.

Medesis Pharma S.A.

L’Orée des Mas
Bât. Les Cyprès Avenue du Golf Baillargues
Montpellier 34670
France
33 4 67 03 03 96
https://www.medesispharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 10

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jean-Claude Maurel M.D., MHB	CEO, President & Member of Management Board	N/A	N/A	N/A
Ms. Tessa Olivato	Member of the Executive Board and Director of Administrative & Financial	N/A	N/A	N/A
Mr. Alexandre Lemoalle	Director of Strategic Partnerships & Member of the Executive Board	N/A	N/A	N/A
Ms. Solene Guilliot	Member of the Executive Board and Director of Medical Affairs & Clinical Development	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Medesis Pharma S.A. operates as a biopharmaceutical company. The company's products include NanoLithium (NP03) for the treatment of Alzheimer's disease; NanosiRNA HD and NanoP42T to treat Huntington's disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma. The company was founded in 2003 and is based in Montpellier, France.

Corporate Governance

Medesis Pharma S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.